Have you or your loved ones been diagnosed with triple negative breast cancer?

You may be eligible to participate in a triple negative breast cancer clinical trial.

Have you or your loved ones been diagnosed with triple negative breast cancer? You may be eligible to participate in a triple negative breast cancer clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Recruiting for this study? Get access to patient recruitment tools.
Triple Negative Breast Cancer Clinical Trial in Madison WI
NCT03733119 | Phase 2 | Interventional

Have you or your loved ones been diagnosed with triple negative breast cancer?

You may be eligible to participate in a triple negative breast cancer clinical trial.

Have you or your loved ones been diagnosed with triple negative breast cancer? You may be eligible to participate in a triple negative breast cancer clinical trial.

Recruiting

Female

18 - 64

Years old

This study is looking to recruit 112 Participants

This phase II trial studies how well Akt/ERK inhibitor ONC201 (ONC201) with or without methionine-restricted (MR) diet works in treating participants with triple negative breast cancer that has spread to other places in the body or cannot be removed by surgery. ONC201 activates a process that leads to the death of a cell. ONC201 is able to target tumor cells to get rid of them, but does not affect normal cells. MR diet is a methionine-free amino acid modified medical food. The addition of an intermittent MR diet may enhance the activity of ONC201. Giving ONC201 and an MR diet may work better in treating participants with breast cancer.

Where you'll go

Selected location

Interested in participating?
Selected location

University of Wisconsin Carbone Cancer Center

600 Highland Avenue, Madison, WI, USA 53792

Renae Quale 608-265-2789
rmq@medicine.wisc.edu


The information you provide is confidential and is never sold or shared with outside vendors. By clicking the button, you agree to the PatientWing's Terms and Privacy Policy.